Clinical trials
Immunotherapy clinical trials
Below are recruiting immunotherapy clinical trials, each written for real people, not researchers. We’re tracking 774 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06414278Recruiting
Spotting early thinking and memory changes with immunotherapy
This study looks at how a special type of immunotherapy called CAR-T therapy might affect your thinking skills, memory, and ability to focus. By checking on patients early and often, the team hopes to find simple ways to detect and manage these side effects sooner.
Minneapolis, MinnesotaAges 18 years+ - NCT05647265RecruitingPhase 2
Immunotherapy before surgery for sarcomatoid pleural mesothelioma
This trial tests adding immunotherapy before surgery to help patients with sarcomatoid pleural mesothelioma. The goal is to shrink or control the cancer and make surgery possible, while checking safety.
Anchorage, AlaskaAges 18 years+ - NCT06807307Recruiting
Using genetic tests to predict immunotherapy response in lung cancer
This study looks at genetic material from tumor samples to find patterns that can predict whether immunotherapy will work for people with advanced non-small cell lung cancer (NSCLC). The goal is to improve how doctors choose treatments for each patient.
RomeAges 18 years+ - NCT06488950RecruitingEarly Phase 1
TIL therapy for advanced solid tumors
This trial tests a new type of personalized cell therapy (TIL) for people with advanced solid tumors who have run out of standard treatment options. It aims to see if this approach can help shrink tumors.
ShanghaiAges 18–75 - NCT07311083Recruiting
Lifestyle program for triple-negative breast cancer patients
This study tests a lifestyle program (diet, exercise, and support) for women with triple-negative breast cancer who are getting chemotherapy plus immunotherapy before surgery. The goal is to see if healthy habits can help during treatment.
Essen, North Rhine-WestphaliaAges 18–75 - NCT07307833Enrolling by invitation
Immune therapy and its effect on balance
This study checks if certain immune therapy drugs affect your balance or inner ear function. It involves people starting treatment with one or two of these drugs for cancer.
Scottsdale, ArizonaAges 18 years+ - NCT07169487RecruitingPhase 1
Methylene Blue for Side Effects of Cancer Immunotherapy
This trial tests if methylene blue can help people who develop side effects called CRS or ICANS after treatments like CAR-T cells or bispecific antibodies. It is a first-in-human study to find a safe dose.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07273708Recruiting
Immune cell study in liver cancer patients on immunotherapy
This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.
Pavia, LombardyAges 18–90 - NCT05699655RecruitingPhase 2/Phase 3
New pre-surgery treatment for advanced stomach cancer with immunotherapy
This trial tests a new combination (tislelizumab plus apatinib and chemotherapy) before surgery for certain advanced stomach cancers, compared with the standard chemotherapy plus S1. The goal is to shrink the tumor and improve outcomes before and around surgery.
Fuzhou, FujianAges 18–75 - NCT06823375RecruitingPhase 2
Radiation plus immunotherapy for liver cancer with major vein clot
This trial tests adding radiation (SBRT) to a combination of immunotherapy drugs (atezolizumab and bevacizumab) for people with liver cancer that has spread into the main portal vein. It aims to see if this approach can shrink tumors and improve outcomes.
Hong KongAges 18 years+ - NCT06924606RecruitingPhase 2
Testing JS207 for advanced lung cancer after prior treatments
This trial tests a new drug called JS207 for people with advanced non-small cell lung cancer (NSCLC) that has gotten worse after standard treatments like chemotherapy and immunotherapy. It aims to see if JS207 can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT05774275RecruitingPhase 1/Phase 2
Testing combined radiation, chemotherapy, and immunotherapy for high-risk sarcoma
This study tests whether giving radiation, chemotherapy, and immunotherapy together can control high-risk soft tissue sarcoma that is hard to remove or may come back after surgery. It may help by attacking cancer in different ways, including boosting the immune system.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04837859RecruitingPhase 2
Personalized immunotherapy for early-stage unfavorable Hodgkin lymphoma
This trial studies a customized immune-based treatment approach for people with early-stage “unfavorable” classical Hodgkin lymphoma who have not had prior treatment. It may help by targeting your lymphoma using an individualized plan based on your case.
CologneAges 18 years+ - NCT06543576RecruitingPhase 1/Phase 2
Radiation and drug therapy for stage IVB cervical cancer
This trial tests combining external and internal radiation with chemotherapy and immunotherapy for stage IVB cervical cancer that has not been treated before. The goal is to see if this approach can help shrink tumors and improve outcomes.
Los Angeles, CaliforniaAges 18 years+ - NCT05754684RecruitingPhase 2
Immunotherapy with donor NK cells for relapsed neuroblastoma
This trial studies a “quadruple immunotherapy” treatment using donor immune cells (NK cells) to fight neuroblastoma that has come back or did not respond to prior therapy. It may help by boosting the body’s immune attack, but only certain children meet the safety and donor requirements.
Hong KongAges Up to 18 years - NCT07231458RecruitingPhase 1
Testing a new immunotherapy with pembrolizumab for advanced solid tumors
This trial tests ABX-001, a new immunotherapy, alone or with pembrolizumab, for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. It may help if your tumor has become resistant to previous immunotherapies.
BerlinAges 18 years+ - NCT03514368Recruiting
Testing immune markers to track cancer treatment safety and benefit
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
ToulouseAges 18 years+ - NCT07082179RecruitingPhase 2
Immunotherapy plus chemotherapy for stage III lung cancer
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
NanjingAges 18–75 - NCT07061379Recruiting
Patient feedback in first-line lung cancer treatment study
This study collects patient feedback through questionnaires to see if it helps improve outcomes for people with advanced non-small-cell lung cancer starting chemo-immunotherapy. It may help your care team better understand how you are feeling.
Milan, ItalyAges 18 years+ - NCT07072351RecruitingPhase 1/Phase 2
Radiation plus chemoimmunotherapy for gastroesophageal junction cancer
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy to shrink gastroesophageal junction cancer before surgery. It aims to make the tumor removable and improve outcomes.
Xiamen, FujianAges 18 years+ - NCT05813418Recruiting
Finding blood and other clues for immune side effects
This study looks for early “predictive clues” (often blood or test markers) that can forecast immune-related side effects in people treated with immune checkpoint medicines. The goal is to help doctors recognize who may be more likely to have these side effects while receiving treatment.
Amiens, PicardieAges 18 years+ - NCT07448077RecruitingPhase 2
Short radiation with immunotherapy for rectal cancer
This trial tests a combination of short-course radiation, chemotherapy, and an immunotherapy drug (Enlonstobart) for patients with a specific type of rectal cancer called pMMR. It aims to see if this approach can shrink tumors before surgery and improve outcomes.
Shijiazhuang, HebeiAges 18 years+ - NCT07496190RecruitingPhase 2
Becotatug Vedotin for advanced nasopharyngeal cancer not responding well to initial treatment
This trial tests a new drug called Becotatug Vedotin for people with locally advanced nasopharyngeal cancer whose tumor did not shrink enough after initial chemotherapy plus immunotherapy. If you qualify, you may receive this targeted therapy to help control the disease.
Guangzhou, GuangdongAges 18–70 - NCT06953843RecruitingPhase 2
Radiation and Immunotherapy for Advanced Lung Cancer
This trial tests a combination of radiation and immunotherapy to see if it can make the immune system attack cancer throughout the body in people with advanced lung cancer that has spread to many places. It's for those whose cancer does not have certain genetic changes and who have not had uncontrolled brain metastases.
Chongqing, Chongqing MunicipalityAges 18–75
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunotherapy?
- Yes. Clin2 currently lists 774 recruiting immunotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.